Hyperfractionated radiotherapy: Tops or flops?

Medical and Pediatric Oncology

Volumn 33, Issue 4, 1999, Pages 399-402

  Baumann, Michael ^a,c   Beck Bornholdt, Hans Peter ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Hyperfractionation; Normal tissue damage; Radiation therapy; Therapeutic ratio; Tumor control

Indexed keywords

CANCER RADIOTHERAPY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; REVIEW;

ANIMALS; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; MULTICENTER STUDIES; NEOPLASMS; RADIATION INJURIES; RANDOMIZED CONTROLLED TRIALS; RATS; TUMOR CELLS, CULTURED;

EID: 0032837236     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199910)33:4<399::AID-MPO10>3.0.CO;2-9     Document Type: Review

References (14)

1. Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 1997;37:259-267.
2. Beck-Bornholdt HP, Dubben HH, Liertz-Petersen C, Willers H. Hyperfractionation: where do we stand? Radiother Oncol 1997; 43:1-21.
3. Baumann M, Bentzen SM, Ang KK. Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. Radiother Oncol 1998;46:127-130.
4. Stuschke M, Thames HD. Hyperfractionation: where do we stand? Radiother Oncol 1998;46:131-133.
5. Herrmann T. Hyperfraktionierte Strahlentherapie: Stand der Forschung. Strahlenther Onkol 1998;174:43-44.
6. Beck-Bornholdt HP, Dubben HH, Petersen C, Willers H. Stellungnahme. Strahlenther Onkol 1998;174:44-45.
7. Willers H, Liertz-Petersen C, Dubben HH, Beck-Bornholdt HP. Outcome of hyperfractionated radiation therapy in randomized clinical trials. Int J Radiat Oncol Biol Phys 1998;40:257.
8. Würschmidt F, Vogler H, Beck-Bornholdt HP. Radiotherapy of the rhabdomyosarcoma R1H of the rat: the influence of the number of fractions on tumour and skin response. Int J Radiat Oncol Biol Phys1988;14:497-502.
9. Petersen C, Baumann M, Dubben HH. et al. Linear-quadratic analysis of tumour response to fractionated radiotherapy: a study on human squamous cell carcinoma xenografts. Int J Radiat Biol 1998;73:197-205.
10. Marcial VA, Pajak TF, Chu C. et al. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys 1987;13:41-47.
11. Datta NR, Choudhry AD, Gupta S, Bose AK. Twice a day versus once a day radiation therapy in head and neck cancer (abstract). Int J Radiact Oncol Biol Phys 1989;17(Suppl 1):132-133.
12. Sanchíz F, Millá A, Tomer J, et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19: 1347-1350.
13. Pinto LHJ, Canary PCV, Araújo CMM, et al. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1991;21:557-562.
14. Horiot JC, Le Fur R, Nguyen TD, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-241.